Insulet grows revenues in Q4
BEDFORD, Mass. – Insulet’s revenues in the fourth quarter of 2013 were $68.5 million, an increase of 19% over the same period in 2012, the company announced Feb. 27. Revenues grew on patient adoption of the OmniPod insulin pump, and despite a reduction in revenues from Neighborhood Diabetes, a subsidiary, due to competitive bidding. Gross profits for the quarter were $33 million, compared to $25.3 million over the same period in 2012. For the year ended Dec. 31, Insulet’s revenues were $247.1 million, a 17% increase over 2012. Gross profit for the year was $112.4 vs. $92.3 million.